ArticleOrphanet journal of rare diseases2025
Benefits and pitfalls in newborn screening for carnitine uptake deficiency: a 4-year single-center experience.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarnitine uptake deficiency (CUD) is an inherited disorder caused by SLC22A5 gene variants resulting in low plasma and intracellular carnitine concentrations. Although newborn screening (NBS) enables a timely diagnosis of CUD, its efficiency is being debated. The aim of this work was to assess the benefits and limitations of NBS for CUD. A retrospective, observational single-center study was conducted on newborns born between 2017 and 2020 recalled for low free carnitine (C0) values. Biochemical, molecular, dietary and perinatal data were collected. Maternal acylcarnitine profiles and SLC22A5 genotype were also recorded, if available.
resultsAmong 160,015 newborns in the study period, forty-six infants were enrolled in the study: three infants were diagnosed with CUD (incidence 1:53,338 newborns), sixteen infants with a maternal disorder, five infants with one heterozygous SLC22A5 variant, and nineteen (41%) infants were false positives. Among false positives, additional factors potentially contributing to the observed low C0 values (i.e., gestational age < 37 weeks, low birth weight, C-section, exclusive breastfeeding) were identified. All enrolled infants were asymptomatic. The association of low C0 with concurrent Ctot values ≤ 19 µmol/L in dried blood spot appeared to argue against a false positive case.
conclusionsCollected data showed that NBS for CUD is burdened by a high false positive rate. Besides individuals with CUD, those with maternal disorders and heterozygous individuals who do not require medical care were also identified. Increasing the efficiency of NBS is a compelling need. Possible strategies to minimize false positives include regular revision of diagnostic cutoffs assessment of fractional excretion of carnitine and implementation of new analytical strategies such as the development of second-tier tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.